WMSA
ALXN

Weiss Multi-Strategy Advisers’s Alexion Pharmaceuticals ALXN Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-5,000
Closed -$461K – 1028
2013
Q2 		$461K Buy
+5,000
New +$482K 0.01% 494

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Weiss Multi-Strategy Advisers's ALXN Position: Q3 2021 in Review

Weiss Multi-Strategy Advisers sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 391,633 shares — an estimated $71.9M sold.

Weiss Multi-Strategy Advisers first reported a position in ALXN in Q3 2013 and held it in 18 quarters. The position peaked at $71.9M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Weiss Multi-Strategy Advisers reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 391,633 Alexion Pharmaceuticals shares in Q3 2021, an estimated $71.9M.
  • Weiss Multi-Strategy Advisers first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 18 quarters.
  • Weiss Multi-Strategy Advisers's Alexion Pharmaceuticals position peaked at $71.9M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q3 2021, filed 15 Nov 2021.